Coronary Artery Disease After Heart Transplantation

• Status: Recruiting
• Trial end date: 2021-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates coronary artery disease after heart transplantation and its relation to platelet function. Furthermore, we will evaluate extracorporeal photopheresis as treatment of coronary artery disease after heart transplantation.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aarhus University Hospital
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Age 18-100

• Informed and signed consent

• Positive Luminex analysis: Blood samples with DSA levels >3000 MFI

• Coronary angiography with evidence of CAV (ISHLT class ≥1) according to ISHLT criteria's.

Exclusion Criteria:

• Severe asthma or COLD with FEV1 < 50%*

• 2° or 3° AV block*

• Pregnancy

• Creatinine >250 mmol/l**

• Platelet count below 20 x 109/L

• History of allergy to 8-Methoxypsoralen (8-MOP)

• History of light-sensitive disease

• These patients will not be subjected to adenosine submission **These patients will not be subjected to OCT evaluation

Control groups:

• 120 patients with angiographically proven coronary artery disease treated with 75 mg aspirin daily for at least seven days (no other antithrombotic drugs are allowed). These data is already available.

• 60 healthy subjects on no medication - samples are taken before and after 75 mg aspirin daily for at least seven days. These data is already available.

As the data regarding the control groups are already available from previous studies at our department, these control patients are no considered actively included in this study. Hence, the patient population consists of the 60 HTx patients.